LuciAle — Alectinib 150 mg, 56 pcs, Lucius

LuciAle — Alectinib 150 mg Capsules, 56 Capsules

Product code: 492

20115₴ 21903₴ -8% On order · from 10 days

Analogues

Alecnib LuciAle
1
Active ingredient
Dosage
150 mg
Dosage form Capsules
Capsules per pack 56

LuciAle is an advanced, highly selective second-generation targeted antineoplastic agent belonging to the anaplastic lymphoma kinase (ALK) inhibitor class, indicated for the treatment of non-small cell lung cancer. The active pharmaceutical ingredient is alectinib at a strength of 150 mg supplied as hard oral capsules (Alectinib Capsules 150 mg). The product is developed and manufactured by Lucius Pharmaceuticals.

Alectinib is a potent, oral, selective tyrosine kinase inhibitor of ALK and RET. It blocks ALK phosphorylation and downstream signaling pathways, inducing tumor cell apoptosis. A crucial clinical advantage of alectinib is its high lipophilicity and ability to effectively cross the blood-brain barrier (BBB), ensuring therapeutic concentrations within central nervous system tissues. Alectinib is highly effective both in ALK inhibitor-naive patients (first-line therapy) and in patients progressing on crizotinib, as well as against central nervous system metastases.

Supplied in a package containing 56 capsules of 150 mg. Intended exclusively for oral administration under the strict supervision of an oncologist.

Key Clinical Features and Advantages of LuciAle 150 mg:

  • ✅ High CNS Penetration: Effectively crosses the blood-brain barrier to control brain metastases.
  • ✅ Overcoming Resistance: Highly effective in patients progressing on prior crizotinib therapy.
  • ✅ Selective Action: Selective inhibition of ALK-positive mutations with minimal off-target kinase toxicity.
  • ✅ Convenient Oral Dosing: Capsules are taken orally twice daily with food.
  • ✅ Lucius Pharmaceuticals Standards: High-quality, accessible generic alternative to the originator product (Alecensa).

LuciAle is supplied as hard capsules for oral administration.

Qualitative and Quantitative Composition per Capsule:

  • Active Ingredient: Alectinib (as alectinib hydrochloride) — 150 mg.
  • Excipients: Lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, sodium lauryl sulfate. Capsule shell: gelatin, titanium dioxide (E171), approved pharmaceutical colorants.

Packaging and Presentation: Hard gelatin capsules containing powder or granules. Each package contains 56 capsules (150 mg) along with prescribing information. Labeled with LuciAle (Alectinib Capsules 150 mg) and Lucius Pharmaceuticals corporate graphics.

Pharmacodynamics:
Alectinib is a highly selective oral tyrosine kinase inhibitor of ALK and RET. In vitro and in vivo, alectinib inhibits ALK kinase activity, leading to blockade of protein phosphorylation, suppression of tumor cell proliferation, and induction of apoptosis in cell lines harboring EML4-ALK gene fusions. Alectinib is also active against ALK mutations, including mutations conferring resistance to crizotinib (such as L1196M and C1156Y).

Pharmacokinetics:

  • Absorption: Rapidly absorbed following oral ingestion with food. Peak plasma concentration (Tmax) is achieved within 4 to 6 hours. Administration with food increases bioavailability approximately 4-fold (must be taken with food!).
  • Distribution: High human plasma protein binding (approximately 99%). Mean volume of distribution is 475 L. Actively penetrates into cerebrospinal fluid.
  • Metabolism: Metabolized primarily in the liver via CYP3A4 to form its major active metabolite M4.
  • Elimination: Excreted predominantly via feces (approx. 98% of dose, with 84% as unchanged drug) and renally (<0.5%). Terminal elimination half-life (T1/2) is approximately 33 hours.

LuciAle is indicated in adult patients for:

  • Non-Small Cell Lung Cancer (NSCLC): Treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced or metastatic non-small cell lung cancer who have not previously received an ALK inhibitor (first-line therapy), as well as patients progressing on prior crizotinib therapy.

LuciAle is administered orally twice daily (every 12 hours) at a total daily dose of 1200 mg.

Dosing Regimen:
The recommended dose is 600 mg (four 150 mg capsules) twice daily (total daily dose of 8 capsules or 1200 mg).

Administration Guidelines:
Capsules must be taken with food and swallowed with water. Capsules must be swallowed whole; do not open, crush, or chew. If a dose is missed or vomiting occurs after ingestion, take the next dose at the scheduled time (do not double doses).

Administration of LuciAle is contraindicated in:

  • Hypersensitivity: Known hypersensitivity to alectinib or any excipient (including lactose intolerance).
  • Pregnancy and Lactation: Contraindicated during pregnancy and breastfeeding.
  • Pediatric Population: Safety and efficacy in patients under 18 years have not been established.
  • Severe Hepatic Impairment: Pronounced liver dysfunction.

Alectinib is metabolized by CYP3A4 and is a substrate for P-glycoprotein and BCRP transporters:

  • Strong CYP3A4 Inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin, grapefruit juice): May elevate alectinib plasma concentrations. Avoid concurrent use or monitor closely.
  • Strong CYP3A4 Inducers (rifampicin, carbamazepine, phenytoin, St. John's Wort): Decrease alectinib blood concentrations, compromising efficacy. Avoid concurrent use.
  • QT-Prolonging Agents: Caution is warranted when co-administered with drugs known to prolong the QT interval.

Pregnancy:
LuciAle is contraindicated during pregnancy. Alectinib exhibits proven embryotoxicity and teratogenic potential. Females of reproductive potential and male partners must utilize effective contraception during treatment and for a specified period post-therapy.

Lactation:
Excretion into human breast milk cannot be ruled out. Breastfeeding must be discontinued during treatment.

The most frequent and clinically significant adverse reactions include:

  • Metabolism & Gastrointestinal: Constipation, nausea, diarrhea, vomiting, elevations in liver transaminases (ALT, AST) and bilirubin.
  • Musculoskeletal: Myalgia, muscle spasms, arthralgia, elevated blood creatine phosphokinase (CPK).
  • General Disorders: Peripheral edema, fatigue, weight gain, rash.
  • Hematologic Toxicity: Anemia, neutropenia, lymphopenia. Routine laboratory monitoring required.
  • Rare but Severe Effects: Pleural effusion, interstitial lung disease (pneumonitis), bradycardia.

Symptoms:
Specific acute overdose symptoms of alectinib are not established. Exaggerated gastrointestinal, hepatic, and musculoskeletal adverse reactions are anticipated.

Treatment:
No specific antidote exists. Supportive and symptomatic care under strict medical supervision should be initiated in case of overdose.

Storage Requirements for LuciAle 150 mg:

  • 🌡️ Temperature Range: Store in a dry place protected from light at temperatures below 30 °C (in original packaging).
  • 👶 Safety Precautions: Keep strictly out of reach of children (cytotoxic antineoplastic agent).
  • ⏳ Shelf Life: Stated on carton and blister/bottle. Do not use past expiration date. Prescription-only oncology medicine.

To verify authenticity of genuine LuciAle 150 mg manufactured by Lucius Pharmaceuticals, inspect the following security and visual features:

  • ✅ Security Hologram & Scratch Code: Outer carton features an official Lucius Pharmaceuticals anti-counterfeit holographic seal with a scratch-off verification code for online validation via the manufacturer's official portal.
  • ✅ Corporate Branding: High-resolution printing displaying Lucius Pharmaceuticals graphics and Alectinib Capsules 150 mg.
  • ✅ Factory Markings: Clearly printed Batch No., Mfg. Date, and Exp. Date matching across outer packaging and inner bottle/blisters.
  • ✅ Prescribing Information: Includes an official product leaflet inside the outer carton.
On order · from 10 days
100% original product
Delivery across Ukraine
1

Notice. The information on this page is for reference only and does not replace medical consultation. Always consult a healthcare professional and read the manufacturer's instructions before using any medicine. Self-medication may be dangerous. Information updated: 14.11.2026

Customer reviews

No reviews yet

Your review can be the first!

Contact us

Choose a convenient way to contact

We work daily from 9:00 to 20:00